Dome-One Maleate (domperidone maleate): Uses, Dosage & Side Effects

What it's for (Indications)

Domperidone maleate is primarily indicated for the symptomatic treatment of nausea and vomiting, including those associated with L-dopa and bromocriptine treatment for Parkinson's disease, and as a prokinetic agent for the management of chronic and subacute gastric motility disorders, such as gastroparesis, where delayed gastric emptying is a significant factor.
Its actions help to restore normal peristalsis and reduce discomfort stemming from upper gastrointestinal dysfunction.
This medication aims to alleviate symptoms arising from impaired upper gastrointestinal motility and reduce the incidence of emetic episodes.

Dosage Information

Type	Guideline
Standard	The dosage of domperidone maleate must be individualized based on the patient's age, weight, renal function, and the specific indication. For adults, the typical oral dosage for nausea and vomiting or gastric motility disorders is 10 mg, taken up to three times daily, approximately 15-30 minutes before meals. The maximum recommended daily dose generally should not exceed 30 mg to mitigate the risk of adverse effects, particularly cardiac arrhythmias. Lower doses or extended dosing intervals may be necessary for patients with moderate to severe hepatic or renal impairment due to reduced drug clearance. It is crucial to adhere strictly to prescribed dosages and not to exceed the maximum daily limit to minimize the potential for serious adverse events.

Type

Guideline

Standard

The dosage of domperidone maleate must be individualized based on the patient's age, weight, renal function, and the specific indication. For adults, the typical oral dosage for nausea and vomiting or gastric motility disorders is 10 mg, taken up to three times daily, approximately 15-30 minutes before meals. The maximum recommended daily dose generally should not exceed 30 mg to mitigate the risk of adverse effects, particularly cardiac arrhythmias. Lower doses or extended dosing intervals may be necessary for patients with moderate to severe hepatic or renal impairment due to reduced drug clearance. It is crucial to adhere strictly to prescribed dosages and not to exceed the maximum daily limit to minimize the potential for serious adverse events.

Safety & Warnings

Common Side Effects

Commonly reported side effects of domperidone maleate include headache, dry mouth, and abdominal cramps.
Less frequently, patients may experience diarrhea, skin rash, pruritus, or drowsiness.
Of greater concern are dose-related or prolonged use-related side effects such as hyperprolactinemia, which can manifest as galactorrhea, gynecomastia, amenorrhea, or sexual dysfunction in both men and women.
While rare in adults, extrapyramidal symptoms (e.
g.
, dystonia, akathisia, parkinsonism) have been observed, particularly in children and adolescents.
The most serious potential side effects involve the cardiovascular system, including prolongation of the QTc interval, which can lead to severe ventricular arrhythmias such as Torsades de Pointes, and sudden cardiac death.
Patients should be advised to report any palpitations, dizziness, or syncope immediately.

Serious Warnings

Black Box Warning: ### SERIOUS WARNINGS: CARDIAC RISKS Domperidone maleate is associated with a dose-dependent risk of serious ventricular arrhythmias, including QTc prolongation, Torsades de Pointes, and sudden cardiac death. This risk is particularly elevated in patients over 60 years of age, those receiving daily doses exceeding 30 mg, and individuals with pre-existing cardiac conditions (e.g., heart failure, significant bradycardia, recent myocardial infarction, uncorrected electrolyte disturbances like hypokalemia or hypomagnesemia), or those concurrently using other QTc-prolonging medicinal products or potent CYP3A4 inhibitors. Due to these significant cardiac risks, domperidone should be used at the lowest effective dose for the shortest possible duration. It is imperative to perform a thorough cardiac risk assessment for all patients before initiating treatment, and to consider the patient's age and overall cardiovascular profile. Concomitant use with medications known to prolong the QT interval or potent CYP3A4 inhibitors is strictly contraindicated. Patients should be advised to promptly report any symptoms that could be associated with cardiac arrhythmias, such as palpitations, dizziness, or syncope, so that the drug can be immediately discontinued and appropriate medical evaluation can be performed. This serious warning underscores the critical importance of careful patient selection, adherence to recommended dosing, and vigilant monitoring during domperidone therapy.
Patients receiving domperidone maleate should be closely monitored for potential adverse reactions, especially those related to cardiac function.
The drug is associated with a risk of QTc interval prolongation, which can precipitate serious ventricular arrhythmias, including Torsades de Pointes, and sudden cardiac death.
This risk is elevated with higher doses, in patients over 60 years of age, in patients with pre-existing cardiac conditions (e.
g.
, heart failure, clinically significant bradycardia), uncorrected electrolyte imbalances (e.
g.
, hypokalemia, hypomagnesemia), or concomitant use of other QTc-prolonging drugs.
Domperidone should be used with extreme caution in patients with hepatic impairment, as drug clearance may be significantly reduced, leading to drug accumulation and increased risk of adverse effects.
Renal impairment also necessitates dose adjustment to avoid accumulation.
Prolonged use or use at doses exceeding recommendations increases the risk of both cardiac and hyperprolactinemic side effects.
Discontinuation should be considered if cardiac symptoms or signs of hyperprolactinemia develop.
Patients should be educated on recognizing and reporting these symptoms promptly.

How it Works (Mechanism of Action)

Domperidone maleate acts primarily as a peripheral dopamine D2 receptor antagonist. Its prokinetic effects are mediated by blocking dopamine receptors in the gastrointestinal tract, which enhances lower esophageal sphincter tone, increases antral and duodenal contractions, and accelerates gastric emptying and small bowel transit. This action helps to reduce gastric distension, reflux, and associated symptoms. The antiemetic properties of domperidone stem from its antagonistic action on dopamine D2 receptors located in the chemoreceptor trigger zone (CTZ), which lies outside the blood-brain barrier. While it minimally penetrates the intact blood-brain barrier, it effectively blocks peripheral dopamine receptors, providing antiemetic and prokinetic benefits with a lower propensity for central nervous system side effects compared to other dopamine antagonists that readily cross the blood-brain barrier.